58228-89-0

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-Cyanophenoxy)propionic Acid is used as an intermediate for the production of various medications. Its unique structure and properties make it a valuable component in the synthesis of pharmaceutical compounds, contributing to the development of new and effective drugs.
Used in Agrochemical Industry:
3-(4-Cyanophenoxy)propionic Acid is also utilized as an intermediate in the production of agrochemicals. Its application in this industry aids in the development of agricultural products, such as pesticides and herbicides, that help improve crop yields and protect plants from pests and diseases.

InChI:InChI=1/C10H9NO3/c11-7-8-1-3-9(4-2-8)14-6-5-10(12)13/h1-4H,5-6H2,(H,12,13)

Upstream product

• 57-57-8 β-Propiolactone 
• 767-00-0 4-cyanophenol 
• 107-94-8 chloropropionic acid 

Downstream Products

• 58228-80-1 3-(4-Cyano-phenoxy)-thiopropionic acid S-tert-butyl ester 
• 138801-92-0 3,4-dihydro-4-oxo-2H-1-benzopyran-6-carbonitrile 
• 1039804-43-7 3-(4-cyanophenoxy)propanoic acid, methyl ester 
• 916303-62-3 3-(4-aminomethyl-phenoxy)-propionic acid 

Relevant academic research and scientific papers

Chroman Compound, Processes for Its Preparation, and Its Pharmaceutical Use

The present invention provided a chroman compound, the method of its preparation and pharmaceutical applications. The compound are represented by formula (I) and its pharmaceutical salt, where in :x is for O or S; n is for 2, 3 or 4; R1 is 6-situ or 7-situ halogen, C1-4alkyl, C1-4alkyoxyl, benzyloxy, acylamino; R2 is nitrogen-containing pentatomic or hexahydric substituted heterocyclic ring. The compound is useful to prepare anti-arrhythmic drugs, the reaction conditions of the method are mild, the raw material are plenty and easy to be obtained, and the operation and post-treatment are simple.

Conformational and Steric Modifications of the Pyran Ring of the Potassium-Channel Activator Cromakalim

The syntheses of analogues of the novel smooth muscle relaxant cromakalim, in which the C-2 methyl groups have been successively replaced by hydrogen, are described and the relative stereochemistry of the two corresponding, isomeric monomethyl compounds,

Spiro hydantoin aldose reductase inhibitors

Sorbitol formation from glucose, catalyzed by the enzyme aldose reductase, is believed to play a role in the development of certain chronic complications of diabetes mellitus. Spiro hydantoin derived from five- and six-membered ketones fused to an aromatic ring or ring system inhibit aldose reductase isolated from calf lens. In vivo these compounds are potent inhibitors of sorbitol formation in sciatic nerves of streptozotocinized rats. Optimum in vivo activity is reached in spiro hydantoins derived from 6-halogenated 2,3-dihydro-4H-1-benzopyran-4-ones (4-chromanones). In 2,4-dihydro-6-fluorospirol[4H-1-benzopyran-4,4'-imidazolidine]-2',5'- ione, the activity resides exclusively in the 4S isomer, compound 115 (CP-45,634, USAN: sorbinil). This compound is currently being used to test, in humans, the value of aldose reductase inhibitors in the therapy of diabetic complications.